World's Best Scientists 2026 revealed!
Alfredo Berruti

Alfredo Berruti

Alfredo Berruti publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Alfredo Berruti sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

The last bar groups every scientist with 1,796 publications or more.

Alfredo Berruti D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Alfredo Berruti sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

The last bar groups every scientist with 217 D-Index or more.

Overview

Alfredo Berruti is affiliated with the University of Brescia in Italy and has authored over 200 publications primarily in the field of Medicine. Their research work spans various subfields including Surgery, Endocrinology, Diabetes and Metabolism, Oncology, Cancer Research, and Pulmonary and Respiratory Medicine.

The main topics of Alfredo Berruti's research include:

  • Adrenal and Paraganglionic Tumors
  • Cancer, Hypoxia, and Metabolism
  • Hormonal Regulation and Hypertension
  • Pituitary Gland Disorders and Treatments
  • Glioma Diagnosis and Treatment
  • Prostate Cancer Treatment and Research
  • Neuroblastoma Research and Treatments

Frequent co-authors in their publications are:

  • Deborah Cosentini
  • Salvatore Grisanti
  • Massimo Terzolo
  • Marta Laganà
  • Sandra Sigala

Alfredo Berruti has contributed several papers published in notable venues, including:

  • Annals of Oncology (12 publications)
  • Cancers (8 publications)
  • ESMO Open (7 publications)
  • Endocrine (6 publications)
  • Endocrine Abstracts (5 publications)

Selected recent papers authored or co-authored by Alfredo Berruti include:

  • "Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up," 2020, Annals of Oncology
  • "Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up," 2020, Annals of Oncology
  • "Contemporary Age-adjusted Incidence and Mortality Rates of Renal Cell Carcinoma: Analysis According to Gender, Race, Stage, Grade, and Histology," 2020, European Urology Focus
  • "Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study," 2023, The Lancet Diabetes & Endocrinology
  • "Efficacy of the EDP-M Scheme Plus Adjunctive Surgery in the Management of Patients with Advanced Adrenocortical Carcinoma: The Brescia Experience," 2020, Cancers

Best Publications

  • Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†.

    S Filetti;C Durante;D Hartl;D Hartl;S Leboulleux;S Leboulleux

  • Combination Chemotherapy in Advanced Adrenocortical Carcinoma

    Martin Fassnacht;Massimo Terzolo;Bruno Allolio;Eric Baudin

  • Adjuvant mitotane treatment for adrenocortical carcinoma.

    Massimo Terzolo;Alberto Angeli;Martin Fassnacht;Fulvia Daffara

  • Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

    Marianne Pavel;Kjell Öberg;Massimo Falconi;Eric Krenning

  • Prevalence of adrenal incidentaloma in a contemporary computerized tomography series

    S. Bovio;A. Cataldi;G. Reimondo;P. Sperone

  • European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors

    Martin Fassnacht;Olaf M. Dekkers;Olaf M. Dekkers;Tobias Else;Eric Baudin;Eric Baudin

  • Changes in Bone Mineral Density, Lean Body Mass and Fat Content as Measured by Dual Energy X-Ray Absorptiometry in Patients With Prostate Cancer Without Apparent Bone Metastases Given Androgen Deprivation Therapy

    Alfredo Berruti;Luigi Dogliotti;Carlo Terrone;Stefania Cerutti

  • Adrenal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    A. Berruti;E. Baudin;H. Gelderblom;H. R. Haak

  • Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial.

    Alfredo Berruti;Massimo Terzolo;Paola Sperone;Anna Pia

  • Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study

    Martin Fassnacht;Alfredo Berruti;Eric Baudin;Michael J Demeure

  • Hypoxia-inducible factor-1alpha expression predicts a poor response to primary chemoendocrine therapy and disease-free survival in primary human breast cancer.

    Daniele Generali;Alfredo Berruti;Maria P Brizzi;Leticia Campo

  • Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up†

    M. Fassnacht;G. Assie;E. Baudin;G. Eisenhofer

  • Pathologic Complete Response As a Potential Surrogate for the Clinical Outcome in Patients With Breast Cancer After Neoadjuvant Therapy: A Meta-Regression of 29 Randomized Prospective Studies

    Alfredo Berruti;Vito Amoroso;Fabio Gallo;Valentina Bertaglia

  • Incidence of skeletal complications in patients with bone metastatic prostate cancer and hormone refractory disease: predictive role of bone resorption and formation markers evaluated at baseline.

    Alfredo Berruti;Luigi Dogliotti;Raffaella Bitossi;Giuseppe Fasolis

  • Retrospective Evaluation of the Outcome of Open Versus Laparoscopic Adrenalectomy for Stage I and II Adrenocortical Cancer

    Francesco Porpiglia;Cristian Fiori;Fulvia Daffara;Barbara Zaggia

  • Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide As Primary Systemic Treatment in Elderly Breast Cancer Patients

    Alberto Bottini;Daniele Generali;Maria Pia Brizzi;Stephen B. Fox

  • Prognostic factors in stage III–IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study

    R. Libé;I. Borget;C.L. Ronchi;B. Zaggia

  • Plasma concentrations of o,p'DDD, o,p'DDA, and o,p'DDE as predictors of tumor response to mitotane in adrenocortical carcinoma: results of a retrospective ENS@T multicenter study.

    Ilse G. Hermsen;Martin Fassnacht;Massimo Terzolo;Saskia Houterman

  • Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial

    Michele Maio;Karl Lewis;Lev Demidov;Mario Mandalà

  • Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24-25 June 2014, Milan

    Gauthier Bouche;Nicolas André;Shripad Banavali;Frank Berthold

Frequent Co-Authors

Massimo Terzolo
Massimo Terzolo University of Turin
Mauro Papotti
Mauro Papotti University of Turin
Francesco Porpiglia
Francesco Porpiglia University of Turin
Stephen B. Fox
Stephen B. Fox Peter MacCallum Cancer Centre
Martin Fassnacht
Martin Fassnacht University of Würzburg
Vittorio Ferrari
Vittorio Ferrari University of Brescia
Giorgio V. Scagliotti
Giorgio V. Scagliotti University of Turin
Eric Baudin
Eric Baudin Institut Gustave Roussy
adrian l harris
adrian l harris University of Oxford
Daniele Santini
Daniele Santini Università Campus Bio-Medico

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Beyond traditional paths in medicine, there are a variety of online programs that open doors to diverse healthcare careers in the USA. Pursuing a health administration degree online can lead to leadership roles in hospitals, clinics, and healthcare organizations, combining patient care with business management.

For those seeking advanced credentials, online mha programs affordable options make it easier to gain specialized expertise in healthcare administration without the burden of high tuition costs. These programs focus on equipping graduates with strong managerial and analytical skills.

If your interests lean toward advanced clinical practice, research, or education, consider the cheapest dnp programs available online. A Doctor of Nursing Practice (DNP) qualifies nurses for top-tier positions and greater responsibility in patient care and healthcare policy.

Similarly, aspiring pharmacists can explore online pharmd programs that provide flexible learning opportunities and prepare graduates for licensure and clinical roles in pharmacy. These related online pathways make it possible to build a rewarding healthcare career with accessibility and affordability in mind.

Best Scientists Citing Alfredo Berruti

Trending Scientists

Recently Published Articles